ARTICLE | Cover Story
Overcoming ibrutinib resistance
August 28, 2014 7:00 AM UTC
Imbruvica ibrutinib's unprecedented response rate in mantle cell lymphoma is generating excitement around the new drug, but as with many targeted cancer therapies, tumors can ultimately become resistant. A recent study from Weill Cornell Medical College suggests that another therapeutic about to hit the market-the cyclin dependent kinase 4 inhibitor palbociclib-could prevent or overcome resistance when used in combination with Imbruvica or a phosphoinositide 3-kinase inhibitor.1
The researchers are now beginning clinical trials to test the different combinations in patients resistant to Imbruvica...